|
钟立业.初诊多发性骨髓瘤治疗模式演变及进展[J].内科急危重症杂志,2025,31(2):160-164
|
| DOI：10.11768/nkjwzzzz20250213 |
| 中文关键词: 多发性骨髓瘤 治疗 模式 |
| 英文关键词: |
| 基金项目: |
|
| 摘要点击次数: 99 |
| 全文下载次数: 110 |
| 中文摘要: |
| 摘要 着新药的涌现，初诊多发性骨髓瘤（NDMM）的治疗模式发生显著变革。诱导治疗中，四联方案（如Dara-VRd）逐渐取代传统三联方案，分层治疗策略因高危患者生存获益需求而动态调整；自体造血干细胞移植（ASCT）在新药时代仍具重要地位，但其时机选择（早期或延迟）及串联移植的适用人群仍需循证支持；维持治疗的个体化趋势显著，来那度胺联合硼替佐米成为高危患者的优选治疗方案。本文结合最新指南及临床试验，系统阐述NDMM治疗模式的演变及未来方向。 |
| 英文摘要: |
| Abstract ith the emergence of new drugs, the treatment paradigm for newly diagnosed multiple myeloma (NDMM) has undergone significant transformation. In induction therapy, quadruplet regimens (e.g., Dara-VRd) have gradually replaced traditional triplet regimens, and stratified treatment strategies are dynamically adjusted to meet the survival benefit needs of high-risk patients. Autologous hematopoietic stem cell transplantation (ASCT) remains crucial in the era of novel agents, though its optimal timing (early vs. delayed) and the appropriate patient population for tandem transplantation still require evidence-based support. The trend toward individualized maintenance therapy is prominent, with lenalidomide combined with bortezomib becoming the preferred choice for high-risk patients. This article systematically reviews the evolution of the NDMM treatment paradigm and future directions, integrating the latest guidelines and clinical trial findings. |
| 本文章附件： | | 附件图表.pdf |
|
|
|
|
